Published on
November 19, 2025
In the media
Our lead oncology asset is nominated for Best Biomedical Product at Prix Galien Bridges Awards, recognizing its potential in advancing cancer therapeutics.
About ÃÛÌÒTV Therapeutics
â€
ÃÛÌÒTV Therapeutics is a clinical-stage biotech company advancing novel antigen modulation ÃÛÌÒTVs for cancer and autoimmune diseases.
â€
The company’s first-in-class small molecules are developed to control T cell activation by modulating antigen presentation, altering how cells appear to the immune system so it can recognize and target them correctly.
â€
ÃÛÌÒTV’s oncology ÃÛÌÒTV (GRWD5769) is delivering promising Phase 1/2 data in patients with solid tumors, demonstrating a strong safety and tolerability profile, as well as generating durable clinical responses across multiple tumor types. The company’s autoimmunity ÃÛÌÒTV (GRWD0715) is progressing in a Phase 1/2 trial to treat the source of axial spondyloarthritis ahead of a planned expansion into other autoimmune indications.
â€
ÃÛÌÒTV is headquartered in Oxford, UK.
â€
More information: Website |
â€
Media enquiries
Patrick White, Head of Communications
â€
